# Seminar 07: Heart Failure ## Year 3: Internal Medicine Clerkship --- ## Learning Objectives By the end of this seminar, students will be able to: 1. Classify heart failure by ejection fraction and stage 2. Describe the pathophysiology of heart failure 3. Recognize clinical presentations of acute and chronic heart failure 4. Apply guideline-directed medical therapy principles 5. Manage acute decompensated heart failure 6. Describe device therapy and advanced heart failure options --- ## Seminar Outline ### I. Definition and Classification Heart failure is a clinical syndrome resulting from structural or functional cardiac abnormalities that impair the heart's ability to fill with or eject blood, leading to the cardinal manifestations of dyspnea, fatigue, and fluid retention. The syndrome encompasses a spectrum of conditions unified by inadequate cardiac output to meet metabolic demands and/or elevated intracardiac filling pressures. Symptoms arise from reduced tissue perfusion causing fatigue and exercise intolerance, and from fluid congestion causing dyspnea, orthopnea, and peripheral edema. Heart failure represents the final common pathway for many cardiovascular diseases including coronary artery disease, hypertension, valvular disorders, and cardiomyopathies. Classification by ejection fraction has important therapeutic and prognostic implications. Heart failure with reduced ejection fraction, defined as left ventricular ejection fraction of 40% or less, represents systolic dysfunction where the ventricle cannot contract effectively. Heart failure with mildly reduced ejection fraction encompasses LVEF of 41-49% and shares features with both reduced and preserved EF categories. Heart failure with preserved ejection fraction, defined as LVEF of 50% or greater, involves diastolic dysfunction with impaired ventricular relaxation and filling despite normal systolic function. A fourth category, heart failure with improved ejection fraction, describes patients whose EF was previously 40% or less but has improved to above 40% with treatment. The ACC/AHA staging system provides a framework for understanding heart failure progression and appropriate interventions at each stage. Stage A includes patients at risk for heart failure due to hypertension, diabetes, coronary artery disease, or cardiotoxin exposure but without structural heart disease or symptoms. Stage B describes patients with structural heart disease such as prior myocardial infarction, left ventricular hypertrophy, or valvular disease but without current or prior symptoms of heart failure. Stage C encompasses patients with structural heart disease and current or prior symptoms of heart failure, representing the population for which most heart failure therapies are indicated. Stage D identifies patients with refractory heart failure requiring specialized interventions including mechanical circulatory support, transplantation, or palliative care. The New York Heart Association functional classification describes symptom severity and exercise tolerance at a given point in time. Class I indicates no limitation of physical activity, with ordinary activity not causing symptoms. Class II represents slight limitation, with symptoms occurring during ordinary activity but none at rest. Class III denotes marked limitation, with symptoms occurring with minimal exertion such as walking short distances or dressing. Class IV describes inability to perform any activity without symptoms or symptoms present at rest. Unlike ACC/AHA staging which only advances, NYHA class can improve or worsen with treatment and disease fluctuations. Panel A: Classification of heart failure by ejection fraction showing HFrEF (40% or less), HFmrEF (41-49%), HFpEF (50% or higher), and HFimpEF with defining characteristics of each. Panel B: ACC/AHA stages A through D illustrated as a progressive continuum with stage-appropriate interventions and therapies at each level. Panel C: NYHA functional classification with descriptions of exercise tolerance and symptom severity for classes I through IV. Panel D: Venn diagram showing the relationship between ACC/AHA stages and NYHA functional classes, demonstrating how patients can have different combinations. --- ### II. Pathophysiology The causes of heart failure with reduced ejection fraction are diverse but share the common feature of impaired systolic function with reduced contractile ability. Ischemic cardiomyopathy from coronary artery disease is the most common cause, resulting from myocardial infarction with resultant scar formation or from chronic ischemia causing hibernating myocardium. Non-ischemic dilated cardiomyopathy may be idiopathic, familial, or secondary to identifiable causes including viral myocarditis, peripartum cardiomyopathy, and chronic tachyarrhythmias. Valvular heart disease including severe mitral or aortic regurgitation causes volume overload leading to ventricular dilation and eventual systolic failure. Toxic cardiomyopathies from alcohol, cocaine, or chemotherapeutic agents such as anthracyclines and trastuzumab represent potentially reversible causes. Heart failure with preserved ejection fraction results from impaired ventricular relaxation and increased stiffness leading to elevated filling pressures despite normal systolic contraction. Chronic hypertension is the most common cause, producing concentric left ventricular hypertrophy with reduced compliance. Age-related changes contribute to myocardial stiffness and impaired relaxation. Obesity-related cardiomyopathy involves both metabolic and mechanical factors affecting diastolic function. Infiltrative diseases including cardiac amyloidosis and constrictive pericarditis cause restrictive physiology. Atrial fibrillation with loss of atrial contribution to ventricular filling exacerbates diastolic dysfunction. Neurohormonal activation represents a central feature of heart failure pathophysiology and a major target for therapy. In response to reduced cardiac output, the renin-angiotensin-aldosterone system is activated, causing vasoconstriction, sodium and water retention, and adverse cardiac remodeling including fibrosis and hypertrophy. Sympathetic nervous system activation increases heart rate and contractility acutely but chronically leads to myocardial toxicity, arrhythmias, and further remodeling. Natriuretic peptides including BNP and ANP are released in response to ventricular stretch, promoting vasodilation and natriuresis to counteract the deleterious neurohormonal activation. Antidiuretic hormone contributes to water retention and hyponatremia in advanced heart failure. Ventricular remodeling describes the progressive changes in cardiac structure that occur in response to injury and hemodynamic stress. Following myocardial infarction, the infarcted region thins and stretches while non-infarcted segments undergo compensatory hypertrophy. Chronic volume overload leads to eccentric hypertrophy with chamber dilation. These geometric changes convert the normal elliptical ventricle to a more spherical shape, increasing wall stress and reducing pumping efficiency. Molecular changes include alterations in contractile proteins, calcium handling, and energy metabolism. Effective medical therapy can produce reverse remodeling with improved geometry, reduced chamber size, and enhanced function. Panel A: Common etiologies of HFrEF and HFpEF organized by mechanism including ischemic, non-ischemic, and infiltrative causes with distinguishing features. Panel B: Diagram of neurohormonal activation in heart failure showing the RAAS cascade, sympathetic nervous system effects, and natriuretic peptide counter-regulation with their clinical consequences. Panel C: Illustration of ventricular remodeling showing progression from normal heart through post-MI changes to dilated cardiomyopathy with corresponding changes in wall thickness, chamber size, and geometry. Panel D: Molecular and cellular targets of heart failure therapy showing how guideline-directed medications interrupt the neurohormonal cascade. --- ### III. Clinical Presentation The symptoms of heart failure reflect the hemodynamic derangements of reduced cardiac output and elevated filling pressures. Dyspnea is the most common symptom, initially occurring with exertion and progressing to dyspnea at rest as heart failure advances. Orthopnea, dyspnea when recumbent that improves with sitting upright, results from redistribution of fluid from the lower extremities to the lungs when supine. Paroxysmal nocturnal dyspnea, awakening from sleep with sudden severe dyspnea, indicates more advanced left heart failure. Fatigue and reduced exercise tolerance reflect inadequate cardiac output to meet metabolic demands. Peripheral edema, abdominal distension from ascites, and right upper quadrant discomfort from hepatic congestion indicate right heart failure. Physical examination findings help assess volume status, cardiac function, and hemodynamic profile. Elevated jugular venous pressure, assessed with the patient at 45 degrees, indicates elevated right atrial pressure and correlates with overall volume status. The S3 gallop, a low-pitched sound heard in early diastole, indicates rapid ventricular filling and is highly specific for left ventricular dysfunction. The S4 gallop, heard in late diastole, indicates reduced ventricular compliance and is common in diastolic dysfunction. Pulmonary crackles or rales indicate alveolar edema, though their absence does not exclude congestion. Peripheral edema in dependent areas, hepatomegaly with hepatojugular reflux, and ascites indicate systemic venous congestion. Assessment of volume status, often described as "wet" or "dry," and perfusion status, described as "warm" or "cold," helps guide management. The warm and wet profile, with adequate perfusion but congestion, is most common and responds to diuresis. The warm and dry profile indicates optimal volume status in a compensated patient. The cold and wet profile, with both reduced perfusion (cool extremities, narrow pulse pressure, altered mentation) and congestion, indicates more severe hemodynamic compromise requiring careful management. The cold and dry profile, with reduced perfusion without congestion, may indicate overdiuresis or primary low output state requiring volume or inotropic support. The Framingham criteria provide a systematic approach to diagnosing heart failure clinically. Major criteria include paroxysmal nocturnal dyspnea, neck vein distension, pulmonary rales, cardiomegaly on chest radiograph, acute pulmonary edema, S3 gallop, increased central venous pressure above 16 cm H2O, hepatojugular reflux, and weight loss greater than 4.5 kg in 5 days with treatment. Minor criteria include bilateral ankle edema, nocturnal cough, dyspnea on ordinary exertion, hepatomegaly, pleural effusion, decrease in vital capacity by one-third, and heart rate greater than 120 beats per minute. Diagnosis requires two major criteria or one major plus two minor criteria, with minor criteria valid only if not attributable to another condition. Panel A: Common symptoms of heart failure organized by mechanism, showing left-sided symptoms (dyspnea, orthopnea, PND) and right-sided symptoms (edema, abdominal distension, early satiety) with their pathophysiologic basis. Panel B: Physical examination technique for jugular venous pressure assessment with interpretation of findings and associated conditions. Panel C: Four-quadrant hemodynamic profile diagram showing warm-wet, warm-dry, cold-wet, and cold-dry states with clinical features and management approach for each. Panel D: Framingham diagnostic criteria organized into major and minor criteria with the rule for diagnosis. --- ### IV. Diagnostic Evaluation The initial diagnostic workup for suspected heart failure aims to confirm the diagnosis, identify the underlying cause, assess severity, and guide treatment decisions. Laboratory studies should include complete blood count to assess for anemia, comprehensive metabolic panel to evaluate renal function and electrolytes, liver function tests to assess for hepatic congestion, thyroid function tests to exclude thyroid disorders, and fasting glucose or hemoglobin A1c for diabetes screening. Iron studies including ferritin and transferrin saturation identify iron deficiency, which is common in heart failure and independently contributes to symptoms and prognosis. Lipid panel and urinalysis complete the routine assessment. Natriuretic peptide measurement with B-type natriuretic peptide or N-terminal pro-BNP is essential in evaluating patients with suspected heart failure. BNP and NT-proBNP are released from ventricular myocytes in response to wall stress, making them sensitive markers for elevated filling pressures. In the acute setting, BNP below 100 pg/mL or NT-proBNP below 300 pg/mL makes heart failure very unlikely as the cause of dyspnea. Elevated levels support the diagnosis, with higher values correlating with greater severity and worse prognosis. However, levels are affected by factors including age, renal function, obesity, and atrial fibrillation, requiring clinical context for interpretation. Serial measurements help assess response to therapy and predict outcomes. Echocardiography is the cornerstone imaging study, providing assessment of ventricular size, wall thickness, systolic function, diastolic function, valvular structure and function, and estimated filling pressures. Left ventricular ejection fraction measurement classifies the heart failure type and guides therapy selection. Wall motion abnormalities suggest ischemic etiology. Diastolic function assessment using tissue Doppler and transmitral flow patterns helps diagnose HFpEF when LVEF is preserved. Valvular abnormalities may be causative or consequential. Right ventricular size and function assessment is increasingly recognized as prognostically important. Chest radiography reveals cardiomegaly, pulmonary vascular congestion, pleural effusions, and pulmonary edema. Additional diagnostic testing is guided by clinical presentation and initial findings. Coronary evaluation with coronary angiography or non-invasive testing is appropriate for patients with new heart failure to assess for ischemic etiology, particularly those with risk factors, anginal symptoms, or wall motion abnormalities. Cardiac MRI provides superior tissue characterization, helping differentiate ischemic from non-ischemic cardiomyopathy through late gadolinium enhancement patterns and identifying specific etiologies such as amyloidosis, sarcoidosis, or myocarditis. Right heart catheterization provides definitive hemodynamic assessment when clinical evaluation is uncertain and guides management in advanced heart failure and transplant evaluation. Panel A: Initial laboratory workup for heart failure showing essential tests, the clinical information each provides, and expected findings in heart failure. Panel B: Algorithm for natriuretic peptide interpretation showing diagnostic cutoffs for BNP and NT-proBNP in acute and ambulatory settings with factors affecting levels. Panel C: Key echocardiographic parameters in heart failure assessment including LVEF, chamber dimensions, wall motion, diastolic function indices, and right heart evaluation. Panel D: Cardiac MRI patterns distinguishing ischemic from non-ischemic cardiomyopathy and identifying specific etiologies through enhancement characteristics. --- ### V. Guideline-Directed Medical Therapy for HFrEF Guideline-directed medical therapy for HFrEF now consists of four pillars of treatment, each providing independent mortality benefit, and all should be initiated in eligible patients. Renin-angiotensin system inhibition forms the first pillar, now preferably with sacubitril/valsartan (angiotensin receptor-neprilysin inhibitor) rather than ACE inhibitors or ARBs alone, based on the PARADIGM-HF trial demonstrating 20% relative risk reduction in cardiovascular death or heart failure hospitalization compared to enalapril. Beta-blockade with evidence-based agents (carvedilol, metoprolol succinate, or bisoprolol) reduces mortality by approximately 30% and should be initiated once patients are euvolemic and titrated to target doses. Mineralocorticoid receptor antagonists (spironolactone or eplerenone) reduce mortality by 30% in patients with LVEF of 35% or less and NYHA class II-IV symptoms. SGLT2 inhibitors (dapagliflozin or empagliflozin) represent the newest pillar, reducing heart failure hospitalization and cardiovascular death regardless of diabetes status. Sacubitril/valsartan combines an ARB with a neprilysin inhibitor, enhancing beneficial natriuretic peptide effects while blocking the deleterious RAAS. It replaces ACE inhibitors or ARBs in patients who tolerate these agents and should be considered first-line for eligible patients with HFrEF. A washout period of at least 36 hours is required after discontinuing an ACE inhibitor before starting sacubitril/valsartan to reduce angioedema risk. Dose titration to target of 97/103 mg twice daily should occur as tolerated, with hypotension being the main limiting side effect. For patients who cannot tolerate or afford sacubitril/valsartan, ACE inhibitors remain effective alternatives, with ARBs reserved for those intolerant of ACE inhibitors. Beta-blockers counteract the deleterious effects of chronic sympathetic activation on the heart. Only carvedilol, metoprolol succinate (extended-release), and bisoprolol have demonstrated mortality benefit and should be used rather than other beta-blockers. Initiation should occur once patients are euvolemic and clinically stable, starting at low doses with gradual uptitration every 2-4 weeks as tolerated to target doses. Beta-blockers should not be started during acute decompensation, and existing therapy should be continued at reduced doses rather than discontinued if possible during hospitalization. Abrupt discontinuation can precipitate clinical deterioration and should be avoided. Additional therapies complement the four pillars in selected patients. Loop diuretics are essential for managing congestion but do not improve mortality and should be used at the lowest effective dose. Hydralazine combined with isosorbide dinitrate provides mortality benefit specifically in Black patients with persistent symptoms despite standard therapy. Digoxin may reduce heart failure hospitalizations and improve symptoms but does not reduce mortality. Ivabradine, which reduces heart rate by inhibiting the sinoatrial node, benefits patients in sinus rhythm with heart rate above 70 despite maximum tolerated beta-blocker. Vericiguat, a soluble guanylate cyclase stimulator, provides additional benefit in high-risk patients with recent worsening heart failure. Panel A: Four pillars of HFrEF therapy showing drug classes, key trial evidence, and mortality reduction for ARNI/ACEi/ARB, beta-blocker, MRA, and SGLT2 inhibitor. Panel B: Sacubitril/valsartan initiation and titration protocol including dosing, contraindications, and ACE inhibitor washout requirements. Panel C: Evidence-based beta-blockers with starting doses, target doses, and titration guidelines. Panel D: Additional HFrEF therapies including diuretics, hydralazine-nitrate combination, digoxin, and ivabradine with their specific indications. --- ### VI. HFpEF Management Heart failure with preserved ejection fraction presents unique therapeutic challenges, as traditional heart failure medications have shown limited benefit until recently. The heterogeneity of HFpEF, encompassing multiple phenotypes with different pathophysiologic mechanisms, partly explains why therapies effective in HFrEF have not uniformly succeeded. Diagnosis requires symptoms and signs of heart failure, LVEF of 50% or higher, and evidence of structural heart disease or diastolic dysfunction, typically with elevated natriuretic peptides. The H2FPEF and HFA-PEFF scores provide diagnostic frameworks for this challenging diagnosis. SGLT2 inhibitors have emerged as the first therapy demonstrating clear benefit in HFpEF. The EMPEROR-Preserved trial demonstrated that empagliflozin reduced the composite of cardiovascular death or heart failure hospitalization by 21% in patients with HFpEF. Similar benefit was observed in the DELIVER trial with dapagliflozin. These agents are now recommended for all patients with HFpEF regardless of diabetes status. The mechanism extends beyond glucose lowering to include favorable effects on cardiac metabolism, loading conditions, and neurohormonal activation. Diuretics remain the cornerstone of symptomatic management, addressing the congestion that causes most symptoms. Loop diuretics are typically required, with dose titrated to achieve and maintain euvolemia. Careful monitoring prevents overdiuresis, which can reduce cardiac output in patients dependent on adequate filling pressures. Blood pressure control is essential, as most HFpEF patients have hypertension as the underlying cause; ACE inhibitors, ARBs, and beta-blockers remain appropriate for hypertension management even without HFpEF-specific benefit. Rate control in atrial fibrillation, present in many HFpEF patients, optimizes diastolic filling time. Management of comorbidities is particularly important in HFpEF, where multiple conditions contribute to the syndrome. Obesity is highly prevalent and contributes to symptoms through multiple mechanisms; weight loss can significantly improve functional capacity and quality of life. Obstructive sleep apnea is common and treatment with CPAP may improve outcomes. Iron deficiency should be identified and treated with intravenous iron when present, as it independently contributes to symptoms and exercise intolerance. Chronic kidney disease frequently coexists and requires coordinated management. Coronary artery disease, if present, may benefit from revascularization in selected patients. Panel A: Diagnostic algorithm for HFpEF including clinical criteria, echocardiographic findings, and natriuretic peptide thresholds with H2FPEF and HFA-PEFF scoring systems. Panel B: SGLT2 inhibitor trial data in HFpEF showing results from EMPEROR-Preserved and DELIVER with outcomes and clinical implications. Panel C: Diuretic management strategy in HFpEF balancing congestion relief against maintenance of adequate filling pressures. Panel D: Comorbidity management in HFpEF showing the impact of treating obesity, sleep apnea, atrial fibrillation, and iron deficiency on symptoms and outcomes. --- ### VII. Acute Decompensated Heart Failure Acute decompensated heart failure represents a clinical syndrome of new or worsening symptoms and signs requiring urgent evaluation and treatment. Precipitating factors should be systematically identified, as addressing these factors is essential for management. Common triggers include medication or dietary nonadherence, acute coronary syndrome, arrhythmias (particularly new-onset atrial fibrillation), uncontrolled hypertension, infection or sepsis, anemia, and thyroid disorders. Identification and treatment of the precipitant often determines the success of therapy and prevents recurrence. Initial assessment should establish the hemodynamic profile using the four-quadrant model of perfusion and congestion. The warm and wet patient, with adequate perfusion but evidence of congestion, is most common and responds to diuretic therapy. The cold and wet patient, with evidence of both hypoperfusion (altered mentation, cool extremities, narrow pulse pressure, oliguria) and congestion, requires more careful management often including inotropic support. The warm and dry patient is compensated and may not require acute intervention beyond optimization of oral therapy. The cold and dry patient, rare and often due to overdiuresis, may require careful volume repletion. Intravenous loop diuretics are the primary treatment for congestion, with dosing guided by the patient's outpatient diuretic regimen. An initial IV dose equivalent to 1-2 times the oral home dose is typical, with reassessment of response guiding subsequent therapy. Continuous infusion may provide more consistent diuresis than intermittent boluses in resistant cases. Addition of a thiazide diuretic (metolazone) to loop diuretics provides synergistic effect through sequential nephron blockade when diuretic resistance occurs. Target net fluid balance should be 3-5 liters negative daily until euvolemia is achieved, with monitoring of renal function and electrolytes. Vasodilator therapy with intravenous nitroglycerin or nitroprusside benefits patients with severe hypertension, acute pulmonary edema, or significant mitral regurgitation. Inotropic agents including dobutamine and milrinone are reserved for cardiogenic shock or low-output states with hypoperfusion, as they increase myocardial oxygen demand and arrhythmia risk. Vasopressors are indicated for cardiogenic shock with persistent hypotension despite inotropic support. Mechanical circulatory support with intra-aortic balloon pump, Impella, or extracorporeal membrane oxygenation provides hemodynamic stabilization as a bridge to recovery, durable support, or transplantation in refractory cases. Panel A: Common precipitants of acute decompensated heart failure organized by category (cardiac, noncardiac, medication-related, and systemic) with evaluation approach for each. Panel B: Four-quadrant hemodynamic assessment showing clinical features and initial management strategy for warm-wet, cold-wet, warm-dry, and cold-dry profiles. Panel C: Diuretic dosing algorithm for ADHF including initial dose selection, response assessment, escalation strategies, and diuretic resistance management. Panel D: Inotrope and vasopressor selection in cardiogenic shock showing hemodynamic effects, indications, and dosing for dobutamine, milrinone, norepinephrine, and dopamine. --- ### VIII. Device Therapy Implantable cardioverter-defibrillators provide primary prevention of sudden cardiac death in patients at elevated risk due to reduced ejection fraction. ICD implantation is indicated for patients with LVEF of 35% or less who have been on optimal guideline-directed medical therapy for at least 3 months and have NYHA class II-III symptoms. A period of at least 40 days post-myocardial infarction or 3 months after coronary revascularization is required before ICD implantation. Life expectancy of greater than one year with good functional status is an important consideration. Secondary prevention indications include survivors of cardiac arrest from ventricular arrhythmia and those with sustained ventricular tachycardia. Cardiac resynchronization therapy improves outcomes in patients with left bundle branch block causing mechanical dyssynchrony. CRT is indicated for patients with LVEF of 35% or less, sinus rhythm, NYHA class II-IV symptoms despite guideline-directed medical therapy, and QRS duration of 150 milliseconds or greater with left bundle branch block morphology. Benefit is most robust with LBBB morphology and wider QRS duration; non-LBBB patterns and narrower QRS show less consistent benefit. CRT can improve ejection fraction by 5-15 percentage points, reduce symptoms, decrease hospitalizations, and improve survival. Most patients receive CRT combined with ICD (CRT-D) for both resynchronization and sudden death protection. The benefits of cardiac resynchronization therapy extend across multiple outcomes when patients are appropriately selected. Symptoms and quality of life improve significantly, often by one or two NYHA functional classes. Left ventricular remodeling improves, with reduction in chamber size and improvement in ejection fraction. Heart failure hospitalizations decrease substantially. Mortality is reduced by approximately 25-30% compared to optimal medical therapy alone. Response rates are highest in patients with native LBBB, wider QRS, and female sex, while patients with non-LBBB morphology or narrower QRS have less predictable benefit. Other devices and advanced therapies may be appropriate for selected patients. Left ventricular assist devices provide mechanical circulatory support either as a bridge to heart transplantation or as destination therapy in patients not eligible for transplant. Percutaneous mitral valve repair with MitraClip may benefit patients with severe secondary mitral regurgitation despite optimal medical therapy. Cardiac contractility modulation delivers electrical signals to improve contractile strength without increasing oxygen demand in patients with narrow QRS who are not CRT candidates. Remote hemodynamic monitoring with implantable pulmonary artery pressure sensors enables proactive management of filling pressures. Panel A: ICD indication criteria showing LVEF threshold, GDMT duration requirement, NYHA class, and timing considerations with decision algorithm. Panel B: CRT indication criteria emphasizing LVEF, QRS duration, morphology, rhythm, and NYHA class with expected response rates by patient characteristics. Panel C: CRT outcomes data showing improvements in symptoms, LVEF, hospitalizations, and mortality with response predictors. Panel D: Overview of advanced device options including LVAD, percutaneous valve therapy, cardiac contractility modulation, and hemodynamic monitoring with appropriate patient selection. --- ### IX. Advanced Heart Failure Advanced heart failure, also termed Stage D heart failure, describes the subset of patients with severe symptoms and functional limitation despite optimal medical and device therapy. Defining characteristics include persistent NYHA class III-IV symptoms with marked limitation of daily activities, recurrent hospitalizations (two or more in the past year) despite optimized therapy, progressive renal dysfunction attributable to cardiac disease, need for inotropic therapy to maintain hemodynamic stability, and consideration for mechanical support or transplantation. These patients have poor prognosis with median survival of 6-12 months without advanced therapies. Heart transplantation remains the definitive therapy for eligible patients with end-stage heart failure, offering excellent long-term survival and quality of life. Indications include end-stage heart failure refractory to medical and device therapy in patients who are otherwise good candidates for major surgery. Contraindications include active malignancy, irreversible pulmonary hypertension, active infection, irreversible severe organ dysfunction (renal, hepatic, pulmonary), active substance abuse, and psychosocial factors precluding compliance with complex post-transplant care. Outcomes have improved substantially, with current median survival exceeding 12 years. However, donor organ scarcity limits availability, and patients often wait months to years on the transplant list. Left ventricular assist devices provide mechanical circulatory support for advanced heart failure either as bridge to transplantation or as destination therapy. As bridge to transplantation, LVADs support patients awaiting donor hearts, improving survival and functional status during the waiting period. Destination therapy provides permanent support for patients who are not transplant candidates due to age, comorbidities, or other factors. Current continuous-flow devices provide excellent hemodynamic support with 2-year survival approaching 70% for destination therapy. Complications include bleeding, infection, stroke, and right ventricular failure, requiring careful patient selection and specialized center management. Palliative care and hospice play essential roles in advanced heart failure management, providing symptom management and quality of life optimization. Integration of palliative care early in the disease course improves symptom control, reduces hospitalizations, and enhances quality of life without shortening survival. Goals of care discussions should occur as heart failure advances, addressing patient preferences for interventions including device deactivation, hospitalization, and end-of-life care. Hospice enrollment is appropriate when prognosis is estimated at six months or less and the focus shifts to comfort rather than disease-modifying therapy. Families benefit from support and guidance throughout the trajectory and into bereavement. Panel A: Criteria for advanced heart failure including symptom severity, hospitalization frequency, inotrope dependence, and organ dysfunction with prognostic implications. Panel B: Heart transplantation indications and contraindications with evaluation process and waiting list management. Panel C: LVAD therapy as bridge to transplant versus destination therapy showing patient selection criteria, device technology, outcomes, and complications. Panel D: Integration of palliative care in heart failure showing timing of discussions, symptom management approaches, and transition to hospice care. --- ### X. Prognosis and Monitoring Multiple factors influence heart failure prognosis, allowing risk stratification to guide management intensity and therapeutic decisions. Lower ejection fraction portends worse prognosis in HFrEF, though this relationship is less clear in HFpEF. NYHA functional class strongly predicts mortality, with class IV patients having 50% annual mortality compared to less than 10% for class I. Natriuretic peptide levels correlate with prognosis, with higher levels and failure to decrease with therapy indicating poorer outcomes. Renal dysfunction, reflected by elevated creatinine or reduced GFR, independently predicts mortality. Hyponatremia below 135 mEq/L indicates advanced neurohormonal activation and worse prognosis. Multiple validated risk scores integrate these factors to estimate prognosis. Outpatient monitoring enables optimization of therapy and early detection of decompensation. Symptom assessment at each visit should include dyspnea, orthopnea, edema, and exercise tolerance, with changes triggering medication adjustment. Daily weight monitoring by patients, with instructions to report gains of more than 2-3 pounds in a day or 5 pounds in a week, enables early intervention for volume accumulation. Blood pressure monitoring guides medication titration. Renal function and electrolytes should be checked 1-2 weeks after medication changes and periodically thereafter. Natriuretic peptides may be checked periodically to assess status, with rising levels sometimes preceding clinical decompensation. Patient education empowers self-management and improves outcomes. Sodium restriction to less than 2 grams daily reduces fluid retention and symptoms, though very strict restriction is no longer recommended. Fluid restriction to 1.5-2 liters daily is appropriate for patients with hyponatremia or refractory congestion despite adequate diuresis. Medication adherence is essential, with patients understanding why each medication is prescribed and the importance of not stopping any without medical guidance. Warning signs requiring prompt medical attention include weight gain, worsening dyspnea, increasing edema, or reduced exercise tolerance. Cardiac rehabilitation improves functional capacity and quality of life and should be offered to stable patients. Care transitions following heart failure hospitalization represent a vulnerable period with high readmission and mortality rates. Follow-up within 7 days of discharge, ideally within 48-72 hours for high-risk patients, reduces readmission risk. Medication reconciliation ensures guideline-directed therapies are continued and appropriately dosed. Volume status reassessment guides diuretic adjustment. Early referral to specialized heart failure programs for patients with advanced disease or frequent hospitalizations improves outcomes. Remote monitoring technologies including implantable hemodynamic monitors and telehealth programs enable proactive management between visits. Panel A: Prognostic factors in heart failure showing mortality risk associated with ejection fraction, NYHA class, natriuretic peptides, renal function, and hyponatremia with risk score integration. Panel B: Outpatient monitoring schedule showing parameters to assess at each visit type including symptoms, weight, blood pressure, labs, and natriuretic peptides. Panel C: Patient education essentials covering sodium and fluid restriction, medication adherence, daily weight monitoring, and warning signs requiring medical attention. Panel D: Care transition best practices following hospitalization including early follow-up, medication reconciliation, and remote monitoring options. --- ## Summary - Heart failure classification: HFrEF (LVEF 40% or less), HFmrEF (41-49%), HFpEF (50% or higher) - ACC/AHA stages progress from A (at risk) through D (advanced/refractory); NYHA class can fluctuate - Neurohormonal activation (RAAS, SNS) drives disease progression and is the target of medical therapy - HFrEF GDMT has four pillars: ARNI or ACEi/ARB, beta-blocker, MRA, and SGLT2 inhibitor; all reduce mortality - Target doses of GDMT should be achieved when possible; all four pillars should be initiated in eligible patients - SGLT2 inhibitors now have evidence in HFpEF and should be used regardless of diabetes status - ADHF management: assess hemodynamic profile (warm/cold, wet/dry), treat congestion with IV diuretics - ICD indicated for LVEF 35% or less on GDMT for 3+ months with NYHA II-III; CRT for wide QRS with LBBB - Advanced heart failure options include LVAD (bridge or destination) and heart transplantation - Close follow-up within 7 days of discharge reduces readmission; daily weights and early symptom recognition are essential --- ## Key Terms | Term | Definition | |------|------------| | HFrEF | Heart failure with reduced ejection fraction; LVEF 40% or less | | HFpEF | Heart failure with preserved ejection fraction; LVEF 50% or higher | | GDMT | Guideline-directed medical therapy; evidence-based treatments improving outcomes | | ARNI | Angiotensin receptor-neprilysin inhibitor; sacubitril/valsartan | | CRT | Cardiac resynchronization therapy; biventricular pacing for dyssynchrony | | ICD | Implantable cardioverter-defibrillator; prevents sudden cardiac death | | LVAD | Left ventricular assist device; mechanical circulatory support | | ADHF | Acute decompensated heart failure; worsening requiring urgent treatment | --- *This content is subject to the [MIT License](https://opensource.org/licenses/MIT). © 2024–2026 Hibbert School of Medicine.*